EP
TNXP icon

Essential Partners’s Tonix Pharmaceuticals TNXP Stock Holding History

Essential Partners’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.1K Buy
1,102
+596
+118% +$7.69K 0.01% 1055
2026
Q1 		$6.96K Buy
+506
New +$7.79K ﹤0.01% 1420

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Essential Partners's TNXP Position: Q2 2026 in Review

Essential Partners increased its Tonix Pharmaceuticals (TNXP) stake by 118% in Q2 2026, buying an estimated $7.69K and bringing the position to 1,102 shares worth $14.1K. The position accounts for 0.01% of the portfolio, ranked #1055.

Essential Partners first reported a position in TNXP in Q1 2026 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • Essential Partners held 1,102 shares of Tonix Pharmaceuticals worth $14.1K as of Q2 2026.
  • Essential Partners bought 596 Tonix Pharmaceuticals shares in Q2 2026, an estimated $7.69K.
  • Tonix Pharmaceuticals made up 0.01% of Essential Partners's portfolio in Q2 2026, its #1055 holding.
  • Essential Partners first reported a position in Tonix Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.